一种新的基于全血细胞计数的评分用于筛查细胞减少症患者中的骨髓增生异常综合征
这项前瞻性研究纳入109例新诊断MDS患者和399例50岁以上确认无MDS的细胞减少症患者,基于平均红细胞体积、中性粒细胞绝对计数和中性粒细胞复杂度及事件分布宽度中位数(Ne-WX)构建MDS-CBC评分,该评分以86%敏感性和88%特异性预测MDS,并在独立验证队列中确认其效能。
要点
- MDS-CBC评分可区分MDS与其他原因细胞减少,敏感性86%、特异性88%。
- 该评分在89%的细胞减少症对照中排除了MDS。
- MDS诊断时评分高值与无事件生存(P=0.02)和总生存(P=0.01)降低显著相关。
核心结论
- MDS-CBC评分是一种简便快速工具,可在分析时对不明原因细胞减少的未选择患者排除或怀疑MDS,并提示进行血涂片检查。
研究设计与样本
- 前瞻性研究纳入109例新诊断MDS患者和399例50岁以上确认无MDS的细胞减少症患者。
- 独立验证队列包括MDS患者34例和细胞减少症对照28例。
主要发现
- 多参数分析显示平均红细胞体积、中性粒细胞绝对计数和中性粒细胞复杂度及事件分布宽度中位数(Ne-WX)在两组间显著不同。
- MDS-CBC评分预测MDS的敏感性为86%,特异性为88%。
- MDS-CBC评分在89%的细胞减少症对照中排除了MDS。
- MDS诊断时评分高值与无事件生存降低显著相关(P=0.02),与总生存降低显著相关(P=0.01)。
关键数值与推荐
- MDS-CBC评分敏感性86%、特异性88%。
- MDS-CBC评分在89%的细胞减少症对照中排除MDS。
- MDS诊断时高评分与无事件生存降低相关(P=0.02)并与总生存降低相关(P=0.01)。
临床怎么用
- 作者认为MDS-CBC评分是简便快速工具,可在分析时对不明原因细胞减少的未选择患者排除或怀疑MDS,并提示进行血涂片检查。
- 作者认为该评分可能改善细胞减少症患者在全血细胞计数评估时进一步MDS特异性检查的分配。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The diagnosis of myelodysplastic syndromes (MDS) is often challenging, time- and resource-consuming. A thorough analysis of complete blood count (CBC) parameters could, however, help to screen for MDS among other causes of cytopenia. To test this hypothesis, 109 newly-diagnosed MDS patients and 399 cytopenic patients older than 50 years with confirmed absence of MDS were enrolled in a prospective study. Multiparametric analysis highlighted three CBC parameters that were significantly different between the two cohorts: mean corpuscular volume, absolute neutrophil count and median neutrophil complexity and width of dispersion of the events measured (Ne-WX), which were used to define an MDS-CBC score. This score enables the prediction of MDS with 86% sensitivity and 88% specificity. The MDS-CBC score excluded MDS in 89% of cytopenic controls. Moreover, high score values at MDS diagnosis significantly correlated with decreased event-free (P = 0·02) and overall survival (P = 0·01). The power of this score was confirmed in an independent validation cohort (MDS n = 34, cytopenic controls n = 28). The MDS-CBC score is an easy and fast tool to exclude or suspect MDS in unselected patients with cytopenia of unknown reasons at the time of analysis, by prompting blood smear examination. It may thus improve allocation of further MDS-specific work-up in patients with cytopenia at the time of CBC assessment.
引用
- Boutault R, Peterlin P, Boubaya M, et al. A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. Br J Haematol. 2018. PMID: 30406952. doi:10.1111/bjh.15626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。